Intrinsic factor deficiency
Also known as: Decreased, Diminished, Inadequate, Under
Methodology & AI Transparency ⓘ
Intrinsic factor deficiency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Anemia, Clotting & Blood Disorders practice, Intrinsic factor deficiency (also termed Decreased or Diminished) (ICD-10 D51.0) is stratified through B12/MMA/folate [Intrinsic factor deficiency D51.0], pairing targeted symptom control with longitudinal Serum Ferritin & in Intrinsic factor deficiency (D51.0: Transferrin Saturation) surveillance.
- 2 Real-world patient consensus: Synonyms for Intrinsic factor deficiency (D51.0): Decreased, Diminished, Inadequate (Blood & Anemia).
- 3 Typical cash cost range: Clinicians assessing Intrinsic factor deficiency focus on impaired erythropoiesis from in Intrinsic factor deficiency (D51.0: iron) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Intrinsic factor deficiency monitoring tracks Hemoglobin, Hematocrit & in Intrinsic factor deficiency (D51.0: MCV) toward Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D51.0).
Ask our AI Specialists anything about Intrinsic factor deficiency
What Is Intrinsic factor deficiency?
Within Anemia, Clotting & Blood Disorders practice, Intrinsic factor deficiency (also termed Decreased or Diminished) (ICD-10 D51.0) is stratified through B12/MMA/folate [Intrinsic factor deficiency D51.0], pairing targeted symptom control with longitudinal Serum Ferritin & in Intrinsic factor deficiency (D51.0: Transferrin Saturation) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
In Intrinsic factor deficiency (D51.0), physiological disruption stems from impaired erythropoiesis from in Intrinsic factor deficiency (D51.0: iron), informing Anemia, Clotting & Blood Disorders protocols that track Serum Ferritin & in Intrinsic factor deficiency (D51.0: Transferrin Saturation) (Ferritin 50–150 ng/mL; TSAT 20%–45% (D51.0)).
Common Symptoms & Clinical Signs
- • Presentation of Intrinsic factor deficiency (D51.0): exertional fatigue, reduced in Intrinsic factor deficiency (D51.0: stamina, pale conjunctiva,)
- • Secondary Intrinsic factor deficiency clinical sign: restless legs, ice in Intrinsic factor deficiency (D51.0: craving)
- • Symptom flares in Intrinsic factor deficiency correlating with Hemoglobin, Hematocrit & in Intrinsic factor deficiency (D51.0: MCV) deviation outside Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D51.0)
- • Functional blood & anemia impact requiring B12/MMA/folate [Intrinsic factor deficiency D51.0] evaluation (D51.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Intrinsic factor deficiency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D51.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin, Hematocrit & in Intrinsic factor deficiency (D51.0: MCV) | Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D51.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Intrinsic factor deficiency (D51.0: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D51.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Intrinsic factor deficiency (D51.0: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D51.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Intrinsic factor deficiency
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nivestym (Filgrastim-Aafi) Nivestym • RxCUI RXN-B00690294 | Leukocyte Growth Factor | 94% | $2.4400 | $ 184.18 /mo |
| Vafseo (Vadadustat) Vafseo • RxCUI RXN-B59922643 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor | 80% | $1.5800 | $ 122.26 /mo |
| Releuko (Filgrastim) Releuko • RxCUI RXN-B701211568 | Leukocyte Growth Factor | 88% | $0.5800 | $ 50.26 /mo |
| Filkri (Filgrastim-Laha) Filkri • RxCUI RXN-B69448009 | Leukocyte Growth Factor | 86% | $1.9400 | $ 148.18 /mo |
| Belzutifan Welireg • RxCUI RXN-00065331-2501 | Hypoxia-inducible Factor Inhibitor | 87% | $3.5700 | $ 153.09 /mo |
| Edoxaban Tosylate Savaysa • RxCUI RXN-65597201-2415 | Factor Xa Inhibitor | 78% | $14.6324 | $ 185.00 /mo |
| Desmoda (Desmopressin Acetate Oral Solution) Desmoda • RxCUI RXN-B71863123 | Factor VIII Activator | 91% | $23.5581 | $ 640.00 /mo |
| Panitumumab Vectibix • RxCUI RXN-55513956-3097 | Epidermal Growth Factor Receptor Antagonist | 85% | $1.5500 | $ 71.28 /mo |
| Vadadustat Vafseo • RxCUI RXN-59922643-2779 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor | 93% | $0.9800 | $ 48.19 /mo |
| Efbemalenograstim Alfa-Vuxw Ryzneuta • RxCUI RXN-72893016-2598 | Leukocyte Growth Factor | 75% | $1.3300 | $ 62.37 /mo |
| Fylnetra (Pegfilgrastim) Fylnetra • RxCUI RXN-B701211627 | Leukocyte Growth Factor | 78% | $1.3200 | $ 103.54 /mo |
| Voydeya (Danicopan) Voydeya • RxCUI RXN-B25682046 | Complement Factor D Inhibitor | 86% | $1.0000 | $ 80.50 /mo |
| Filgrastim-Txid Nypozi Txid, Nypozi • RxCUI 2700369 | Leukocyte Growth Factor | 78% | $1.3700 | $ 63.99 /mo |
| Axatilimab-Csfr Niktimvo • RxCUI RXN-50881023-2650 | Colony Stimulating Factor-1 Receptor Blocker | 93% | $1.5100 | $ 69.66 /mo |
| Cetuximab Erbitux • RxCUI 1657658 | Epidermal Growth Factor Receptor Antagonist | 91% | $0.4500 | $ 26.73 /mo |
| Welireg (Belzutifan) Welireg • RxCUI RXN-B00065331 | Hypoxia-inducible Factor Inhibitor | 88% | $2.7200 | $ 204.34 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Intrinsic factor deficiency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause:: What a 1,022-Participant Study Found None of the intrinsic and extrinsic factors analyzed substantially reduced the efficacy response to fezolinetant in SKYLIGHT 1 and 2. Menopause (New York, N.Y.) • 2024-04-01 • Phase III Randomized Trial | N = 1,022 | 96/100 | PMID 38517210 ↗ |
| New Insights on Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the: What a 672-Participant Study Found In this retrospective exploratory analysis of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer, each intrinsic subtype exhibited a consistent PFS benefit with RIB, except. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2021-05-01 • Phase III Randomized Trial | N = 672 | 93/100 | PMID 33769862 ↗ |
| Can This Approach Help? Inside the Latest Research on Influences of resting-state intrinsic functional brain connectivity on the Response to antidepressants in LLD is related to connectivity in the DMN, cognitive control and limbic networks. Psychological medicine • 2023-10-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 36482694 ↗ |
| Can This Approach Help? Inside the Latest Research on Baclofen Modulates Neural Intrinsic Functional Connectivity in Treatment-Seeking High-dose baclofen may modulate intrinsic brain connectivity in key networks implicated in AUD, including systems involved in attention and stress regulation. Alcohol, clinical & experimental research • 2026-06-15 • Phase III Randomized Trial | N = 29 | 88/100 | PMID 42246466 ↗ |
| Can This Approach Help? Inside the Latest Research on Intrinsic connectomes are a predictive biomarker of full symptom relief in In contrast, connectivity for remitters was higher than controls at baseline and also following full symptom relief, suggesting a trait-like connectomic characteristic. Molecular psychiatry • 2020-07-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 31695168 ↗ |
Intrinsic factor deficiency Patient Community & “People Like Me” Threads
Filter Intrinsic factor deficiency community threads and patient logs by age, biological sex, dosage, and treatment duration.